Show simple item record

Brief report: three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC - Update from PACIFIC

dc.contributor.authorGray, JE
dc.contributor.authorVillegas, A
dc.contributor.authorDaniel, D
dc.contributor.authorVicente, D
dc.contributor.authorMurakami, S
dc.contributor.authorHui, R
dc.contributor.authorKurata, T
dc.contributor.authorChiappori, A
dc.contributor.authorLee, KH
dc.contributor.authorCho, BC
dc.contributor.authorPlanchard, D
dc.contributor.authorPaz-Ares, L
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorVansteenkiste, JF
dc.contributor.authorSpigel, DR
dc.contributor.authorWadsworth, C
dc.contributor.authorTaboada, M
dc.contributor.authorDennis, PA
dc.contributor.authorOzguroglu, M
dc.contributor.authorAntonia, SJ
dc.date.accessioned2019-11-19T15:51:26Z
dc.date.available2019-11-19T15:51:26Z
dc.date.issued2019en
dc.identifier.citationGray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Brief report: three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC - Update from PACIFIC. J Thorac Oncol. 2019.en
dc.identifier.pmid31622733en
dc.identifier.doi10.1016/j.jtho.2019.10.002en
dc.identifier.urihttp://hdl.handle.net/10541/622319
dc.descriptionen]
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.jtho.2019.10.002en
dc.titleBrief report: three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC - Update from PACIFICen
dc.typeArticleen
dc.contributor.departmentH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.en
dc.identifier.journalJournal of Thoracic Oncologyen
refterms.dateFOA2019-11-25T21:55:39Z


Files in this item

Thumbnail
Name:
1-s2.0-S1556086419335294-main.pdf
Size:
1.308Mb
Format:
PDF
Description:
Full text, Open Access article
Download

This item appears in the following Collection(s)

Show simple item record